ClinicalTrials.gg
TerminatedNCT06747273DISCOVERYUpdated Nov 10, 2026

Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States

A Phase 1 interventional study of SRP-9004 in Limb Girdle Muscular Dystrophy and Limb Girdle Muscular Dystrophy Type 2D/R3, sponsored by Sarepta Therapeutics, Inc.. Terminated at 2 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Study is being terminated due to a business decision.

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States — 3 open to participants now, 9 under way, 1 of them phase 3. Muscular Dystrophies, Limb-Girdle · United States.

Enrollment
14th of 17
4 · median 11
Started
2025
with 1 other
Phase 1
5 of 30
none open now
Registered
29th of 30
by date
Lead sponsor
8 of 30
Sarepta Therapeutics, Inc.

Among the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, this one is the 14th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 1, and was the 29th registered.

Muscular Dystrophies, Limb-Girdle

47 studies on the registry are indexed under Muscular Dystrophies, Limb-Girdle; 10 are open to participants now.

Browse Muscular Dystrophies, Limb-Girdle studies →

Open to participants now

3 of the 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Muscular Dystrophies, Limb-Girdle studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Muscular Dystrophies, Limb-Girdle with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety of SRP-9004.

03

Conditions studied

  • Limb Girdle Muscular Dystrophy
  • Limb Girdle Muscular Dystrophy Type 2D/R3

Keywords

  • Limb Girdle Muscular Dystrophy Type 2D/R3
  • SRP-9004
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ambulatory participants, defined as able to walk without assistive aid, 10MWR \<30 seconds, and NSAD total score ≥25; non-ambulatory participant, defined as 10MWR ≥30 seconds or unable to perform, and PUL 2.0 entry scale score ≥3.
  • Ambulatory participants must be 4 to 20 years of age and the non-ambulatory participant must be ≥4 years of age.
  • All participants must be ≤70 kilograms
  • Possess 1 homozygous or 2 heterozygous pathogenic and/or likely pathogenic α-SG deoxyribonucleic acid (DNA) gene mutations as documented prior to screening.
  • Able to cooperate with muscle testing.
  • Participants must have adeno-associated virus (AAV) serotype Rh74 (rh74) antibody titers \<1:400 (that is, not elevated) as determined by an enzyme-linked immunosorbent assay (ELISA).

Key Exclusion Criteria:

  • \<40% or clinical signs and/or symptoms of cardiomyopathy
  • FVC ≤40% of predicted value and/or requirement for nocturnal ventilation
  • Any other illness, including neuromuscular (other than limb girdle muscular dystrophy type 2D/R3 [LGMD2D/R3]), that in the opinion of the Investigator might compromise the participant's ability to comply with the protocol required testing or procedures or compromise the participant's wellbeing, safety, or clinical interpretability.

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    SRP-9004

    Participants will receive a single dose of SRP-9004 on Day 1.

    Drug: SRP-9004

Interventions

  • DrugSRP-9004

    Intravenous (IV) infusion.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs), Adverse Events of Special Interest (AESI) and Treatment-emergent Serious Adverse Events (SAEs)

    Time frame: Up to 60 months

Secondary outcomes

  1. Change from Baseline Through Day 60 in Quantity of Alpha-sarcoglycan (α-SG) Protein Expression

    Time frame: Baseline, Day 60

  2. Change from Baseline Through Month 24 in Quantity of α-SG Protein Expression

    Time frame: Baseline, Month 24

  3. Change from Baseline Through Month 60 in North Star Assessment for Dysferlinopathy (NSAD) Total Score

    Time frame: Baseline, Month 60

  4. Change from Baseline Through Month 60 in Performance of the Upper Limb (PUL) Version 2.0 Total Score

    Time frame: Baseline, Month 60

  5. Change from Baseline Through Month 60 in Time to Rise From Floor

    Time frame: Baseline, Month 60

  6. Change from Baseline Through Month 60 in Time to Ascend 4 Steps

    Time frame: Baseline, Month 60

  7. Change from Baseline Through Month 60 in Time to Complete 10-meter Walk/Run (10MWR)

    Time frame: Baseline, Month 60

  8. Change from Baseline Through Month 60 in Time to Complete 100-meter Walk/Run (100MWR)

    Time frame: Baseline, Month 60

  9. Change from Baseline through Month 60 in Creatine Kinase (CK) Level

    Time frame: Baseline, Month 60

  10. Time to Change of Disease Milestones (Loss of Ambulation)

    Time frame: Baseline, Month 60

  11. Change from Baseline Through Month 60 in Skeletal Muscle Magnetic Resonance Imagining (MRI) Findings

    Time frame: Baseline, Month 60

  12. Change from Baseline Through Month 60 in Wearable Device Stride Velocity 95% (SV95C) (Ambulatory Participants Only)

    Time frame: Baseline, Month 60

  13. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Vital Capacity (FVC)

    Time frame: Baseline, Month 60

  14. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by FVC Percentage (%) Predicted

    Time frame: Baseline, Month 60

  15. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Baseline, Month 60

  16. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by FEV1 % Predicted

    Time frame: Baseline, Month 60

  17. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Peak Expiratory Flow Rate (PEFR)

    Time frame: Baseline, Month 60

  18. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Maximal Inspiratory Pressure (MIP)

    Time frame: Baseline, Month 60

  19. Change from Baseline Through Month 60 in Pulmonary Functions as Assessed by Maximal Expiratory Pressure (MEP)

    Time frame: Baseline, Month 60

07

Study locations

2 sites
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23510, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in Jun 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 24, 2024
StartActual
Jan 9, 2025
Primary completionActual
Jun 18, 2025
CompletionActual
Jun 18, 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and references
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06747273
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jan 9, 2025
Primary completion
Jun 18, 2025
Completion
Jun 18, 2025
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion